22 Oct 2026, 08:39 IST
Divi's Laboratories Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · BUY · target ₹10,800
The report cites peptide API demand growth from oral Wegovy and favorable US tariff treatment as supporting a BUY call on Divi's Labs with 14% upside and a stop loss at ₹8,870.
From MOStMarketOutlook22102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.